PT  - JOURNAL ARTICLE
AU  - Gill, Christopher J
AU  - Mwananyanda, Lawrence
AU  - MacLeod, William
AU  - Kwenda, Geoffrey
AU  - Pieciak, Rachel
AU  - Etter, Lauren
AU  - Bridges, Daniel J.
AU  - Chikoti, Chilufya
AU  - Chirwa, Sarah
AU  - Chimoga, Charles
AU  - Forman, Leah
AU  - Katowa, Ben
AU  - Lapidot, Rotem
AU  - Lungu, James
AU  - Matoba, Japhet
AU  - Mwinga, Gift
AU  - Mubemba, Benjamin
AU  - Mupila, Zachariah
AU  - Muleya, Walter
AU  - Mwenda, Mulenga
AU  - Ngoma, Benard
AU  - Nkazwe, Ruth
AU  - Nzara, Diana
AU  - Pawlak, Natalie
AU  - Pemba, Lillian
AU  - Saasa, Ngonda
AU  - Simulundu, Edgar
AU  - Yankonde, Baron
AU  - Thea, Donald M.
TI  - Sustained high prevalence of COVID-19 deaths from a systematic post-mortem study in Lusaka, Zambia: one year later
AID  - 10.1101/2022.03.08.22272087
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.08.22272087
4099  - http://medrxiv.org/content/early/2022/03/22/2022.03.08.22272087.short
4100  - http://medrxiv.org/content/early/2022/03/22/2022.03.08.22272087.full
AB  - Background Sparse data documenting the impact of COVID-19 in Africa has fostered the belief that COVID-19 ‘skipped Africa’. We previously published results from a systematic postmortem surveillance at a busy inner-city morgue in Lusaka, Zambia. Between June-October 2020, we detected COVID-19 in 15-19% of all deaths and concentrated in community settings where testing for COVID-19 was absent. Yet these conclusions rested on a small cohort of 70 COVID-19+ decedents. Subsequently, we conducted a longer and far larger follow-on survey using and expanding on the same methodology.Methods We obtained a nasopharyngeal swab from each enrolled decedent and tested these using reverse transcriptase quantitative PCR (RT-qPCR). A subset of samples with a PCR cycle threshold <30 underwent genotyping to identify viral lineages. We weighted our results to adjust for enrolment ratios and stratified them by setting (facility vs. community), time of year, age, and location.Results From 1,118 enrolled decedents, COVID-19 was detected among 32.0% (358/1,116). We observed three waves of transmission that peaked in July 2020, January 2021, and ∼June 2021 (end of surveillance). These were dominated by the AE.1 lineage and the Beta and Delta variants, respectively. During peak transmission, COVID-19 was detected in ∼90% of all deaths. Roughly four COVID-19 deaths occurred in the community for every facility death. Antemortem testing occurred for 52.6% (302/574) of facility deaths but only 1.8% (10/544) of community deaths and overall, only ∼10% of COVID-19+ deaths were identified in life.Conclusions COVID-19 had a devastating impact in Lusaka. COVID-19+ deaths occurred in all age groups and was the leading cause of death during peak transmission periods. Testing was rarely done for the vast majority of COVID-19 deaths that occurred in the community, yielding a substantial undercount.What is already known on this topicPreviously, we reported that COVID-19 was present among 15-19% of all decedents passing through a busy city morgue in Lusaka.Data documenting the mortal impact of COVID-19 in Africa remain sparse.Several modeling groups have also argued that COVID-19’s impact in Africa has been underreported and hence underestimated.What this study addsAntemortem testing for COVID-19 captured only ∼10% of COVID-19 positive individuals indicating a substantial gap in surveillance.During peak transmission periods, ∼90% of all deceased individuals tested positive for COVID-19.Most COVID-19 positive deceased adults presented with symptoms typical of COVID-19, arguing that COVID-19 caused their deaths and was not a co-incidental finding.Deaths occurred across the age spectrum, including among young children, indicating a different pattern of impact from what has been seen in high income country settings.We document three waves of transmission, attributable to the AE.1 lineage, and the Beta and Delta variants, respectively.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe original ZPRIME study and this covid-19 expansion were made possible through the generous support of the Bill & Melinda Gates Foundation (OPP 1163027). The funders had no role in designing the study; in the collection and analysis of data; or in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Boston University Medical Center gave ethical approval for this work Ethics committee/IRB of University of Zambia gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors